Company intelligence / Profile preview
Neuromagen Pharma
Beer-Sheva, Israel
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Lead candidate AGS-499 received FDA Orphan Drug Designation for ALS in May 2022. The drug has shown significant effectiveness in delaying the onset and progression of ALS in mouse models and neuronal cells from ALS patients. The company plans to submit an IND for first-in-human clinical trials of AGS-499 for ALS, expected during 2024.
- Therapeutic areas
- CardiovascularEndocrinologyDermatologyWomen's HealthNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Neuromagen Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Neuromagen Pharma.